Awards Honor Innovation and Excellence in Pharmaceutical and Biomedical Industries

PALO ALTO, Calif., March XX, 2020 – Neumentum, Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that it has been nominated for two Informa Pharma Intelligence Citeline Awards including the Most Successful Early Stage Research and Clinical Trial Result of the Year categories.

The Citeline Awards, previously known as the CARE Awards, recognize the outstanding contributions of those in clinical research and development who are improving human lives worldwide through discovery and development of new drugs.  The awards celebrate excellence among companies, teams, and individuals who are driving innovative change in the pharmaceutical and biomedical industries.

The Citeline Awards focus on honoring the strategic thinkers, risk takers, and innovators who persist in pushing for new breakthroughs in medicine. These individuals and companies are looking for cures, extending lives, or alleviating human suffering.  Neumentum and their partner Clinical Research Organization, NEMA Research Inc., were nominated together for the recent phase 1 clinical study on NTM-001, Neumentum’s lead non-opioid pain product.

NTM-001 is a novel, alcohol-free formulation of ketorolac in a pre-mixed bag for continuous IV infusion that has the potential to treat moderately severe acute pain that requires analgesia at the opioid level for up to 24 hours, usually in a postoperative setting, and to reduce the need for opioids.

Opioid use is considered a critical public health concern in the US.  In 2018, 10.3 million people misused prescription opioid pain relievers[1]. More than 70 million surgical procedures are performed in the U.S. annually and postsurgical pain is routinely treated with opioid analgesics.  The results of the NTM-001 study support what has the potential to be the first-ever non-steroidal anti-inflammatory drug (NSAID) approved for continuous infusion.  If approved, NTM-001 has the possibility of reducing or eliminating the need for opioids in the post-surgical setting where there is a need for non-opioid options.

Citeline award winners will be announced on April 30, 2020 at the Hyatt Regency in Boston, Massachusetts. The Citeline award is sponsored by both Informa Pharma Intelligence, a leader in providing timely intelligence about the drug development pipeline to pharmaceutical and biomedical decision makers around the world, and Citeline, part of Informa’s Pharma Intelligence vertical, a comprehensive source of real-time R&D intelligence for the pharmaceutical industry.

Neumentum:  Addressing a National Health Emergency

On average, more than 1,000 people are treated each day in emergency rooms for misusing prescription opioids, and 46 people die every day from prescription opioid overdoses[2].   More than 70 million surgical procedures are performed in the U.S. annually and postsurgical pain is routinely treated with opioid analgesics.  America’s opioid crisis has been declared a national public health emergency.

Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company with product candidates that have the potential to provide the benefits of safe and effective pain management without the limitations and risks for abuse and misuse that come with opioids.  Neumentum’s lead product candidate, NTM-001 (novel, alcohol-free formulation of ketorolac in a pre-mixed bag for continuous IV infusion), has the potential to treat moderately severe acute pain that requires analgesia at the opioid level for up to 24 hours, usually in a postoperative setting, and to reduce the need for opioids. Additionally, NTM-006, a product that is neither an opioid nor a NSAID, has completed positive Phase 2A clinical studies for moderate to moderately severe acute pain. Neumentum is led by a world-wide executive team of biotech and pharmaceutical industry leaders who have extensive experience in pain and neurology, from drug development through commercialization. For more information, visit Neumentum.com.

# # #

INVESTOR CONTACT: 
Scott Shively
CEO & Co-founder
scottshively@neumentum.com
(833) NEUPAIN

 

MEDIA CONTACT:
Patty Leitch
Communications
917-865-0232
patricialeitch@neumentum.com
(833) NEUPAIN


[1] CDC website, 2019 National Survey on Drug Use and Health. Mortality in the United States, 2018

[2] CDC website, Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and Opioid-Involved Overdose Deaths – United States, 2013-2017. Morb Mortal Wkly Rep. ePub: 21 December 2018)